Natural history of stage I non-small cell lung cancer: implications for early detection
- PMID: 17505036
- DOI: 10.1378/chest.06-3096
Natural history of stage I non-small cell lung cancer: implications for early detection
Abstract
Background: Concern has been raised that early detection of lung cancer may lead to the treatment of clinically indolent cancers. No population-based study has examined the natural history of patients with stage I NSCLC who receive no surgery, chemotherapy, or radiation therapy. Our hypothesis is that long-term survival in patients with untreated stage I non-small cell lung cancer (NSCLC) is uncommon.
Methods: A total of 101,844 incident cases of NSCLC in the California Cancer Center registry between 1989 and 2003 were analyzed; 19,702 patients had stage I disease, of whom 1,432 did not undergo surgical resection or receive treatment with chemotherapy or radiation. Five-year overall survival (OS) and lung cancer-specific survival were determined for this untreated group, for subsets of patients who were recommended but refused surgical resection, and for T1 tumors.
Results: Only 42 patients with untreated stage I NSCLC were alive 5 years after diagnosis. Five-year OS for untreated stage I NSCLC was 6% overall, 9% for T1 tumors, and 11% for patients who refused surgical resection. Five-year lung cancer-specific survival rates were 16%, 23%, and 22%, respectively. Among these untreated patients, median survival was 9 months overall, 13 months for patients with T1 disease, and 14 months for patients who refused surgical resection.
Conclusion: Long-term survival with untreated stage I NSCLC is uncommon, and the vast majority of untreated patients die of lung cancer. Given that median survival is only 13 months in patients with T1 disease, surgical resection or other ablative therapies should not be delayed even in patients with small lung cancers.
Comment in
-
Natural history of stage I lung cancer.Chest. 2007 Dec;132(6):2062; author reply 2062-3. doi: 10.1378/chest.07-2032. Chest. 2007. PMID: 18079253 No abstract available.
Similar articles
-
An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1438-43. doi: 10.1016/j.ijrobp.2004.12.038. Int J Radiat Oncol Biol Phys. 2005. PMID: 16029805
-
Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.Southeast Asian J Trop Med Public Health. 2005 Jul;36(4):994-1006. Southeast Asian J Trop Med Public Health. 2005. PMID: 16295558
-
Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):348-53. doi: 10.1016/j.ijrobp.2011.06.2003. Epub 2011 Nov 19. Int J Radiat Oncol Biol Phys. 2012. PMID: 22104360
-
Treatment of stage I and II non-small-cell lung cancer.Cancer Control. 2001 Jul-Aug;8(4):318-25. doi: 10.1177/107327480100800403. Cancer Control. 2001. PMID: 11483885 Review.
-
Advances in the Treatment of Stage III Non-Small Cell Lung Cancer.Clin Chest Med. 2020 Jun;41(2):211-222. doi: 10.1016/j.ccm.2020.02.008. Clin Chest Med. 2020. PMID: 32402357 Review.
Cited by
-
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?J Immunother Cancer. 2021 Jun;9(6):e002248. doi: 10.1136/jitc-2020-002248. J Immunother Cancer. 2021. PMID: 34083418 Free PMC article. Review.
-
The value of preoperative positron emission tomography/computed tomography in differentiating the invasive degree of hypometabolic lung adenocarcinoma.BMC Med Imaging. 2023 Feb 10;23(1):31. doi: 10.1186/s12880-023-00986-8. BMC Med Imaging. 2023. PMID: 36765284 Free PMC article.
-
miR‑10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.Oncol Rep. 2020 Jun;43(6):1906-1914. doi: 10.3892/or.2020.7547. Epub 2020 Mar 17. Oncol Rep. 2020. PMID: 32186774 Free PMC article.
-
Survival after radiofrequency ablation and/or chemotherapy for lung cancer and pulmonary metastases: a systematic review and meta-analysis.Front Immunol. 2023 Oct 6;14:1240149. doi: 10.3389/fimmu.2023.1240149. eCollection 2023. Front Immunol. 2023. PMID: 37869011 Free PMC article.
-
Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity.Cancer Manag Res. 2018 Jan 24;10:167-175. doi: 10.2147/CMAR.S151935. eCollection 2018. Cancer Manag Res. 2018. PMID: 29416376 Free PMC article.